BioCardia Receives Nasdaq Minimum Bid Price Deficiency Notice
BCDA sits 35% above its 52-week low of $0.75.
Summary
BioCardia received a Nasdaq minimum bid price deficiency notice, giving it until February 16, 2027, to regain compliance. The stock has traded below $1.00 for 30 consecutive business days.
Key Events · Legal and Risk Events · BCDA
-
Nasdaq Deficiency Notice
On August 19, 2026, BioCardia received a notice that its stock traded below $1.00 for 30 consecutive business days, violating Nasdaq's minimum bid price rule.
-
Compliance Deadline
The company has 180 calendar days, until February 16, 2027, to regain compliance by closing at or above $1.00 for ten consecutive business days.
-
Delisting Risk
If compliance is not regained, BioCardia may be eligible for a second 180-day period, but would likely need to effect a reverse stock split to qualify.
-
Prior Extension Superseded
This new notice supersedes the Nasdaq extension granted on June 12, 2026, which had a compliance deadline of October 7, 2026.
Analysis · BCDA · Life Sciences
A new Nasdaq deficiency notice landed on August 19, 2026, after BioCardia's stock traded below $1.00 for 30 consecutive business days. The company now has until February 16, 2027, to regain compliance by trading at or above $1.00 for ten consecutive business days. This supersedes the prior extension granted in June 2026 and puts delisting risk back in focus. The company may pursue a reverse stock split if needed, but no assurance is given.
At the time of this filing, BCDA was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.75 to $2.29. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.